Imricor Medical Systems (IMR) H1 2026 earnings summary

Executive summary

• Achieved a pivotal milestone with the U.S. commercial launch, securing first customers and expanding the sales team, with several hospitals in advanced purchasing stages.

• Launched the Imricor Cardiovascular business vertical, targeting over 2,250 U.S. hospitals and expanding addressable markets beyond electrophysiology.

• Maintained a strong balance sheet with net cash of nearly US$70 million, funding operations into 2028.

• Achieved four FDA clearances in 1H26, including pediatric label expansions for NorthStar and Vision-MR Diagnostic Catheter.

• U.S. commercial team expansion underway to support growth.

Financial highlights

• Q2 2026 revenue was US$60.5k–$61k, down 6% year-over-year, reflecting ongoing clinical trial enrollments not recognized as revenue.

• Net loss for the quarter was US$7.4m, a 5% improvement year-over-year, primarily due to lower non-cash charges.

• Adjusted net loss (excluding fair value and FX) was US$7.0m, up 38% year-over-year, driven by increased operating expenses.

• Operating cash outflow was US$6.1m, down from US$7.9m in Q1 2026.

• Cash and marketable securities at quarter-end totaled US$67.5m, rising to nearly US$70m post-quarter from exercised options.

Outlook and guidance

• Focus for H2 CY2026 is on converting the U.S. hospital pipeline into NorthStar sales and scaling commercial operations.

• Multiple FDA decisions expected in 2H26 to complete the U.S. platform, including additional capital equipment clearances.

• Completion of the VISABL-AFL trial and final PMA module submission targeted.

• Plans to expand NorthStar installations, leveraging new Philips compatibility and targeting both pediatric and adult hospitals.

• Launch of Imricor Finance vendor financing program to facilitate hospital purchases.